14-day Premium Trial Subscription Try For FreeTry Free
Date Action Amount Person Type
Dec 19, 2019 Buy 123 000 Hulme Allison Common Stock (Right to Buy)
Jun 27, 2019 Buy 20 000 Proehl Gerald T Stock Option (Right to Buy)
Jun 27, 2019 Buy 20 000 Heppell James L Stock Option (Right to Buy)
Jun 27, 2019 Buy 20 000 Ekman Lars Stock Option (Right to Buy)
Dec 31, 2018 Buy 245 000 Hulme Allison Common Stock (Right to Buy)
Jun 27, 2018 Buy 20 000 Proehl Gerald T Stock Option (Right to Buy)
Jun 27, 2018 Buy 20 000 Heppell James L Stock Option (Right to Buy)
Jun 27, 2018 Buy 20 000 Ekman Lars Stock Option (Right to Buy)
Dec 06, 2017 Buy 8 000 Hulme Allison Common Stock (Right to Buy)
May 30, 2017 Buy 20 000 Proehl Gerald T Stock Option (Right to Buy)
May 30, 2017 Buy 20 000 Heppell James L Stock Option (Right to Buy)
May 30, 2017 Buy 20 000 Ekman Lars Stock Option (Right to Buy)
Dec 07, 2016 Buy 206 000 Hulme Allison Common Stock (Right to Buy)
Oct 27, 2016 Buy 38 Heppell James L Common Shares
Jul 28, 2016 Buy 1 318 Heppell James L Common Shares
May 27, 2016 Buy 103 467 Hulme Allison Common Stock (Right to Buy)
May 27, 2016 Buy 8 250 Proehl Gerald T Stock Option (Right to Buy)
May 27, 2016 Buy 8 250 Heppell James L Stock Option (Right to Buy)
May 27, 2016 Buy 8 250 Ekman Lars Stock Option (Right to Buy)
May 27, 2015 Buy 8 250 Turner Joseph L Stock Option (Right to Buy)
May 27, 2015 Buy 8 250 Proehl Gerald T Stock Option (Right to Buy)
May 27, 2015 Buy 8 250 Heppell James L Stock Option (Right to Buy)
May 27, 2015 Buy 8 250 Ekman Lars Stock Option (Right to Buy)
Feb 05, 2015 Buy 45 481 Hulme Allison Common Stock (Right to Buy)
Dec 18, 2014 Sell 9 663 Ekman Lars Common Stock
Dec 15, 2014 Sell 796 772 Boxer Capital, Llc Common Stock
Dec 15, 2014 Sell 84 707 Boxer Capital, Llc Common Stock
Sep 19, 2014 Buy 10 000 Proehl Gerald T Common Stock
Jun 17, 2014 Buy 6 329 Turner Joseph L Stock Option (Right to Buy)
Jun 17, 2014 Buy 1 627 Proehl Gerald T Stock Option (Right to Buy)
Jun 17, 2014 Buy 8 250 Heppell James L Stock Option (Right to Buy)
Jun 17, 2014 Buy 8 250 Ekman Lars Stock Option (Right to Buy)
Jun 06, 2014 Sell 19 231 Heppell James L Common Stock
Mar 24, 2014 Buy 16 500 Proehl Gerald T Stock Option (Right to Buy)
Mar 19, 2014 Buy 0 Proehl Gerald T
Oct 25, 2013 Buy 178 641 Hulme Allison Common Stock (Right to Buy)
Oct 25, 2013 Buy 430 375 Hulme Allison Common Stock (Right to Buy)
Oct 25, 2013 Buy 16 500 Turner Joseph L Stock Option (Right to Buy)
Oct 25, 2013 Buy 16 500 Heppell James L Stock Option (Right to Buy)
Oct 25, 2013 Buy 16 500 Ekman Lars Stock Option (Right to Buy)
Aug 23, 2013 Buy 0 Turner Joseph L
Aug 16, 2013 Buy 0 Heppell James L Common Shares
Aug 16, 2013 Buy 0 Heppell James L Common Stock
Aug 16, 2013 Buy 1 450 000 Boxer Capital, Llc Common Stock
Aug 16, 2013 Buy 150 000 Boxer Capital, Llc Common Stock
Aug 16, 2013 Buy 0 Boxer Capital, Llc Common Stock
Aug 16, 2013 Buy 0 Boxer Capital, Llc Common Stock
Aug 16, 2013 Buy 16 306 Hulme Allison Stock Option (right to buy)
Aug 16, 2013 Buy 0 Heppell James L Common Stock
Aug 16, 2013 Buy 0 Heppell James L Common Stock
Aug 16, 2013 Buy 0 Heppell James L Common Stock
Aug 16, 2013 Buy 0 Heppell James L Common Stock
Aug 16, 2013 Buy 0 Heppell James L Common Stock
Aug 16, 2013 Buy 0 Ekman Lars Common Stock
Sep 30, 2012 Buy 3 846 Hulme Allison Stock Option (right to buy)
Jun 09, 2012 Buy 9 615 Ekman Lars Stock Option (right to buy)
Feb 16, 2012 Buy 576 Heppell James L Stock Option (right to buy)
Feb 16, 2012 Buy 1 730 Ekman Lars Stock Option (right to buy)
Mar 16, 2010 Buy 2 344 Heppell James L Common Share Purchase Warrant
Sep 03, 2009 Buy 1 826 Heppell James L Stock Option (right to buy)
INSIDER POWER
0
Last 60 transactions
Buy: 3 315 769 | Sell: 910 373 (Shares)

Based on the 60 latest insides trades, we have calculated the insider power to be negative at a ratio of 0.000.

In total, the insiders bought 3 315 769 and sold 910 373 SPHS shares in the last 60 trades.

Click to get the best stock tips daily for free!

About Sophiris Bio

Sophiris Bio Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pha... SPHS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT